Stocktoria

Grace Therapeutics, Inc. GRCE

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2013-03-07

Grace Therapeutics, Inc. statistics & valuation

Market cap$38.7M
P / B0.6×
Return on equity-12.2%
Return on capital-17.2%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
20192020202120222023202420252026
Operating margin (%)
-8377.00% -15.60% 20192020202120222023202420252026
Return on equity (%)
-356.40% -196.30% -35.40% -9.10% -62.40% -20.80% -14.40% -12.20% 20192020202120222023202420252026
Shares outstanding
78.1M 44.3M 7.4M 9.5M 13.7M 16.5M 20192020202120222023202420252026
Net debt ($)
20192020202120222023202420252026
Share buybacks ($)
20192020202120222023202420252026
Return on assets (%)
-106.70% -111.60% -31.50% -7.60% -53.60% -17.50% -13.30% -11.70% 20192020202120222023202420252026
Free cash flow margin (%)
20192020202120222023202420252026
Debt / equity (×)
20192020202120222023202420252026
EPS ($)
-$0.27 -$5.71 -$1.35 -$0.79 -$0.47 20192020202120222023202420252026

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating margin————-15.6%-8377.0%——
Net margin————-9.8%-10039.8%——
Return on assets-11.7%-13.3%-17.5%-53.6%-7.6%-31.5%-111.6%-106.7%
Return on equity-12.2%-14.4%-20.8%-62.4%-9.1%-35.4%-196.3%-356.4%
Current ratio8.1011.7714.268.5913.8939.502.502.05

Computed from company filings · US · as of 2026-03-31. Facts plus Stocktoria's own computed scores — not investment advice.